Savara Pharmaceuticals focuses on the development of an inhaled antibiotic for autoimmune pulmonary alveolar proteinosis (aPAP).
3
Funding Rounds
$16.3m
Money raised
The company Savara Pharmaceuticals has raised a total of $7.73m in funding over 3 rounds.